1754 results about "Obesity" patented technology

The invention provides a polypeptide or a derivative and a pharmaceutically acceptable salt thereof. The amino acid sequence of the polypeptide is as shown in SEQ ID NO: 1. The polypeptide or the derivative and the pharmaceutically acceptable salt thereof disclosed by the invention can be combined with GLP-1R and GCGR, and is used for effectively activating the GLP-1R and the GCGR. Therefore, the polypeptide or the derivative and the pharmaceutically acceptable salt thereof can be used for detecting GLP-1R and / or GCGR, and can also be used for treating or preventing GLP-1R and / or GCGR related diseases (such as metabolic disorder related diseases, such as obesity, diabetes, fatty liver diseases, non-alcoholic fatty liver diseases and the like).

The invention discloses an intestinal flora and obesity personalized diagnosis method based on a graph attention network, and relates to the technical field of obesity diagnosis, and the method comprises the following steps: collecting gene data, building a graph structure-based model for the data to predict obesity risk and provide personalized health suggestions, each piece of microbiome data is expressed as a weighted undirected graph, a microbiome graph is constructed, the association strength between microbiome groups is calculated, and the microbiome data is expressed as a graph structure. According to the method, the graph structure model considering the relevance between the microbiome groups is constructed, the self-adaptive graph convolutional network and the heterogeneous graph attention network are utilized, multi-modal information interaction between the microbiome and clinical data is deeply mined, the processing capacity of high-dimensional and complex microbiome data is improved, and the multi-modal information interaction between the microbiome and clinical data is improved. The accurate prediction of obesity risks and the provision of personalized health suggestions are realized, the prediction accuracy and generalization ability of the model are significantly improved, and a more effective personalized obesity diagnosis effect is achieved.

Disclosed are methods of improving treatment adherence and compliance after discontinuation of incretin-based therapies, such as GLP-1 and / or GIP agonists, using pharmacotherapies comprising the disclosed therapeutic compounds and combinations. In some aspects, methods include treatment of psychological factors affecting other medical conditions (PFAOMC) following the administration of incretin-based therapies to treat obesity or hyperglycemia, and related disorders. In some aspects, disclosed pharmacotherapies for use in the methods include agents that modulate monoaminergic neurotransmission, administered alone or together, such as in disclosed combinations having advantageous synergistic effects.

Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

The invention relates to the technical field of medical image processing, and discloses a human body abdominal fat analysis method based on a medical image, which comprises the following steps: acquiring multi-modal medical image data such as CT (Computed Tomography), MRI (Magnetic Resonance Imaging) and ultrasonic images, constructing a fusion database through multi-scale affine transformation alignment, de-noising by using a model based on a residual self-encoder, and enhancing a boundary in combination with Canny edge detection. A segmentation model is constructed based on an improved U-Net architecture, multi-modal features are fused, and a dynamic convolution kernel and a channel attention mechanism are used for optimization. A quantitative analysis model is established by adopting a multi-task joint learning framework, gradient conflicts are solved, and a lightweight sub-network is searched and generated. Carrying out uncertainty modeling on the segmentation model, and carrying out active learning annotation to optimize the performance. A multi-granularity feature fusion framework is designed, anatomical priori knowledge is embedded to construct an association graph, a structured analysis report is generated, abdominal fat can be accurately analyzed, and diagnosis and treatment of obesity-related diseases are assisted.

Provided in the present invention are a tetrahydropyridopyrazole derivative and use thereof in medicine. Specifically provided is a compound as shown in general formula (I) or a racemate, stereoisomer, tautomer, deuterated substance, solvate, prodrug, metabolite, pharmaceutically acceptable salt or eutectic crystal thereof, an intermediate thereof, a preparation method therefor, and use thereof in the preparation of a related drug for treating diabetes or obesity.

Embodiments of the present invention provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue. In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion, or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective to injure or damage tissue, nerves, and nerve endings in order to relieve disease symptoms.

The invention discloses a BMI-driven 3D organ obesity visualization system based on multi-modal fusion, and relates to the technical field of medical science, the system comprises a BMI-driven prediction model, the BMI-driven prediction model is used for establishing a quantitative mapping model of a BMI index and three-dimensional organ fat deposition, and the quantitative mapping model is used for establishing a BMI index and three-dimensional organ fat deposition. The BMI driving type prediction model comprises a multi-modal data fusion unit, a model mapping unit and a residual compensation unit. By installing the BMI driving type prediction model, precise nonlinear mapping of the BMI index and organ fat deposition is achieved, the problem that traditional single-mode prediction is large in deviation is solved, and organ fat volume prediction precision and individual difference adaptability are improved.

To provide a device and a method for treating at least one of hypertension, pulmonary arteries, diabetes, obesity, heart failure, end-stage renal disease, digestive disease, urological disease, cancers, tumors, pain, asthma or chronic obstructive pulmonary disease by delivering an effective amount of a formulation to a tissue.SOLUTION: In embodiments of the present invention, the formulation may include at least one of a gas, a vapor, a liquid, a solution, an emulsion or a suspension of one or more ingredients. In embodiments of the present invention, amounts of the formulation and / or energy are effective in injuring or damaging tissue, nerves and nerve endings in order to relieve disease symptoms.SELECTED DRAWING: Figure 3B

A class of compounds and the use thereof in a drug. Specifically, the present invention relates to a class of new compounds, a pharmaceutical composition containing the compounds, a method for preparing the compounds, and the use of the compounds or the pharmaceutical composition in the preparation of a drug for treating GLP-1 receptor agonist-mediated diseases and / or disorders, particularly the use in the preparation of a drug for treating diabetes, non-alcoholic fatty liver disease, obesity, myocardial infarction, heart failure, diabetic nephropathy, Parkinson's disease and Alzheimer's disease.

The present invention relates to immunoglobulins, such as immunoconjugates, comprising an ActRII receptor antibody and an agonistic GLP-1 molecule, such as agonistic GLP-1 peptide. Such constructs are useful in the treatment of numerous diseases and disorders, including metabolic disorders, such as obesity, diabetes and others.

The invention relates to the field of biological medicine, in particular to application of hispidulin in preparation of a lipid de novo synthesis inhibitor or a metabolism-related fatty liver disease treatment or prevention product. The hispidulin disclosed by the invention has a chemical structure as shown in a formula (I). The hispidulin in the invention reverses liver cell lipid droplet excessive infiltration induced by high-dose fructose in a dose-dependent manner; furthermore, the hispidulin dose-dependent ameliorating obesity signs in HFD-induced MAFLD model mice, including liver weight, body weight, blood lipid level, liver fat content, and insulin resistance, without significantly reducing food intake.

Described herein are GLP-1R agonists and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of a GLP-1 associated disease or disorder, including Type 2 diabetes or obesity.

The invention features polypeptides that include an extracellular ActRIIa variant. In some embodiments, a polypeptide of the invention includes an extracellular ActRIIa variant fused to an Fc domain monomer or moiety. The invention also features pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions involving weakness and atrophy of muscles, e.g., Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy, inclusion body myositis, amyotrophic lateral sclerosis, sarcopenia; or cancer cachexia; or metabolic diseases, e.g., obesity, Type-1 diabetes, or Type-2 diabetes.

The invention discloses a steroid compound as well as a preparation method and application thereof. The invention specifically discloses a steroid compound with a structure as shown in a formula I and the like or a pharmaceutically acceptable salt of the steroid compound. The compound provided by the invention has SREBP pathway inhibitory activity, and can be used for preventing and / or treating obesity, hyperlipidemia, fatty liver, diabetes, atherosclerosis, cardiovascular and cerebrovascular diseases, liver cancer, skin injury and other diseases. # imgabs0 #

An α-amylase inhibitory peptide. The peptide comprises amino acid sequences of eight adjacent amino acids X1, X2, X3, X4, X5, X6, X7, and X8, wherein each amino acid of the peptide is independently selected from a D-amino acid or an L-amino acid, and at least one of X2, X4, and X6 is W. The peptide has α-amylase inhibitory activity, has the effects of losing weight and lowering blood sugar, and can be used for preparing α-amylase inhibitors, weight-losing drugs, hypoglycemic drugs, or foods, health-care products or drugs for preventing or treating obesity-related diseases.

An apparatus for treating obesity in a human or animal mammal patient. The apparatus comprising a first volume filling device segment and a second volume filling device segment. The first and second volume filling device segments are adapted to be assembled into an implantable volume filling device of a controlled size. Each one of the first and second volume filling device segment comprises at least one interconnecting structure. The interconnecting structure of the second volume filling device segment is adapted to be formed fitted, such that the first and second volume filling device segment can be assembled into the volume filling device. The assembled volume filling device is adapted to be at least substantially invaginated by a stomach wall portion of a patient, with the outer surface of the device resting against the stomach wall, such that the volume of the food cavity is reduced in size.

Provided are compounds of Formula (I) and pharmaceutical compositions thereof, for use in, e.g. treating type 2 diabetes mellitus, pre-diabetes, obesity, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and cardiovascular disease.

A compound of formula (I) or (Ia), or a tautomer or a pharmaceutically acceptable salt thereof is provided. Compounds of formula (II) to (V), or a tautomer or a pharmaceutically acceptable salt thereof are also provided. These compounds and the pharmaceutical compositions containing them are useful for the treatment of diseases such as obesity, hyperlipidemia, hypercholesterolemia and diabetes and other related disorders and diseases, and may be useful for other diseases such as NASH, atherosclerosis, cardiovascular diseases, hypothyroidism, thyroid cancer and other disorders and diseases related thereto. (I), (Ia)

The invention relates to a pharmaceutical composition. The pharmaceutical composition comprises a PCSK9 inhibitor and a GLP-1 receptor agonist, the invention also relates to application of the medicine composition in preparation of medicines for treating hyperglycemia, diabetes, obesity and / or cholesterol-related diseases.

The invention discloses a children obesity early warning method and system based on obesity risk factor analysis, and the method comprises the steps: carrying out the feature screening of collected children multi-dimensional health related data containing parental information, birth history and lifestyle, and recognizing the important risk factors and weights of children obesity; important risk factors are supplemented through literature review; the method comprises the following steps: formulating scale questions including parental information, birth history and lifestyle based on important risk factors and weights in combination with clinical expert opinions, assigning scores to the scale questions, dividing according to a scale score result to form children obesity risk prediction levels, and providing personalized health management schemes for subjects with different risk levels. The method is low in cost, easy to implement, high in compliance and based on non-invasive characteristics, and is particularly suitable for early obesity screening and early warning of 3-6-year-old children.

The present disclosure provides a novel class of compounds having GPR75 ligand 20-HETE production inhibitory activity, pharmaceutical compositions containing the compounds, useful intermediates for preparing the compounds, and methods of treating obesity using the compounds of the disclosure.

The invention discloses application of fisetin or a salt thereof in medicine preparation, the compound is used for treating or preventing obesity cardiomyopathy, preferably heart diseases caused by hyperlipidemia, but is not limited to the inducer, and specifically, the medicine can inhibit or improve various obesity cardiomyopathy.

The invention relates to a weight loss intervention method and device for chronic renal failure and obesity patients based on an individualized prescription. The method comprises the following steps: constructing a multi-modal dynamic time sequence feature vector of a patient; identifying and quantifying potential causal effects of different weight loss intervention measures on physiological outcomes of renal functions, electrolyte balance, anemia states, bone mineral metabolism and weight indexes of the CKD patient according to a dual robust estimator; dynamically constructing a weight loss intervention measure causal model according to the potential causal effect of the physiological outcome of each patient and the physiological and pathological background; and inputting the multi-modal dynamic time sequence feature vector of the patient into a weight loss intervention measure causal model, and generating a daily diet scheme, an exercise scheme and corresponding high-confidence risk early warning and causal explanation of the patient. The method overcomes the limitation that the traditional method only pays attention to correlation and cannot clearly determine the intervention effect, ensures that the causal atlas and the intervention scheme are optimized according to the real-time change state of the patient, and realizes a real dynamic prescription.

The invention provides a polypeptide and application thereof in preparation of an alpha-glucosidase inhibitor. The invention finds that the polypeptide with the amino acid sequence as shown in SEQ ID NO: 1 has excellent alpha-glucosidase inhibitory activity and DPPH free radical scavenging activity, that is, the polypeptide is suitable for preparing an alpha-glucosidase inhibitor and an antioxidant product, so that diabetes and / or obesity can be effectively prevented and / or treated, and the application prospect is broad. According to the present invention, the polypeptide resource library having the alpha-glucosidase inhibition effect and / or the anti-oxidation effect can be enriched, and more raw material choices can be provided for the alpha-glucosidase inhibitor, the anti-oxidation product, the diabetes prevention and / or treatment product, and the obesity prevention and / or treatment product.

The invention discloses a composite microbial preparation for treating obesity of pet dogs and application of the composite microbial preparation, and belongs to the technical field of microbial preparations. The compound microbial preparation is prepared by fermenting lactobacillus acidophilus L100 and lactobacillus reuteri GBW1146, and the preservation number of the lactobacillus reuteri GBW1146 is CGMCC (China General Microbiological Culture Collection Center) No. 34455. The compound microbial preparation is prepared by fermenting lactobacillus acidophilus L100 and lactobacillus reuteri GBW1146. The compound microbial preparation can remarkably reduce digestion and absorption of intestinal tracts of dogs on fat and reduce triglyceride and cholesterol levels in blood, so that the average food intake and average calorie consumption of the dogs are reduced, and finally the effect of reducing obesity of the pets is achieved. The compound microbial preparation provided by the invention enhances the competitiveness of the pet feed additive and series products thereof in China in the international market, and has a wide application prospect.

The invention relates to the technical field of microorganisms, in particular to lactococcus lactis subsp. Lactis JYLL-51 for improving sarcopenia obesity as well as a microbial agent and application of the lactococcus lactis subsp. Lactis JYLL-51. The Lactococcus lactis subsp. Lactis JYLL-51 is preserved in China General Microbiological Culture Collection Center (CGMCC) on March 13, 2024, the preservation address is No.3, Yard 1, Beichen West Road, Chaoyang District, Beijing, and the preservation number is CGMCC NO.30016. The Lactococcus lactis subsp. Lactis JYLL-51 has the advantages that the Lactococcus lactis subsp. Lactis JYLL-51 can be used for preparing the Lactococcus lactis subsp. Lactis JYLL-51; the invention provides a lactococcus lactis subsp. Lactis JYLL-51, and experiments show that the lactococcus lactis subsp. Lactis JYLL-51 microbial inoculum prepared from the strain can not only improve the weight and strength of skeletal muscle, but also reduce fat accumulation induced by high fat, and can significantly improve sarcopenia obesity.

The present disclosure relates to methods for treating obesity and / or methods for reducing and maintaining body weight and / or body fat in a patient in need thereof.

The invention belongs to the technical field of medical instruments, and particularly relates to a cryoablation catheter and an ablation system.The cryoablation catheter comprises an inner catheter body and an outer catheter body, the outer catheter body is coaxially arranged on the outer side of the inner catheter body in a sleeving mode, and the inner catheter body is configured to be of a multi-cavity structure; the multiple plugging assemblies are arranged on the outer side of the inner catheter; wherein in the initial state, the multiple plugging assemblies and the inner catheter are located in the outer catheter, and in the working state, the multiple plugging assemblies and the inner wall of the intestinal tract jointly form an ablation closed space. The cryoablation catheter is guided to a target position through the guide wire, the closed ablation space is formed through cooperation of the plugging assembly and the inner wall of the cavity, a freezing medium is input into the closed ablation space to conduct cryoablation on the inner wall of the cavity, an available treatment scheme is provided for patients suffering from type 2 diabetes, obesity or other cavity lesions, and meanwhile the treatment effect is improved. The device has the advantages of small trauma, less pain of patients, low surgical risk and the like.

Described herein is a method of treating a disease or condition, for example, obesity, weight gain, or diabetes, comprising administering to a subject in need thereof a glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonist and a glucagon-like peptide 1 receptor (GLP-1R) agonist. Further described herein are pharmaceutical compositions comprising a GIPR antagonist and a GLP-1R agonist, which may be useful in the treatment of a disease or condition, for example, obesity, weight gain, or diabetes.